Investor Moves
| Name | Value | Action | Change | Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-24.6K ExitQ1 2026 $25k -- $0.45 | |||||
News
prnewswire.comScinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiativesprnewswire.comJun 10
prnewswire.comScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facilityprnewswire.comMay 20
prnewswire.comScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europeprnewswire.comMay 15
benzinga.comWhy Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Todaybenzinga.comApr 24
prnewswire.comScinai Immunotherapeutics Announces $2.61 Million Private Placement Financingprnewswire.comApr 24